NTLA vs. PRME

Last updated Apr 1, 2026

Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Prime Medicine Inc. Common Stock (PRME).

Performance

NTLA vs. PRME - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Prime Medicine Inc. Common Stock (PRME). The values are adjusted to include any dividend payments, if applicable.

NTLA vs. PRME - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
NTLA Intellia Therapeutics, Inc.	42.60%	-22.90%	-61.76%	-12.61%	-29.36%
PRME Prime Medicine Inc. Common Stock	0.29%	18.84%	-67.04%	-52.31%	20.88%

Fundamentals

Market Cap NTLA : $1.39B PRME : $517.68M
EPS NTLA : -$3.84 PRME : -$1.38
PB Ratio NTLA : 2.07 PRME : 4.28
Total Revenue (TTM) NTLA : $0.00 PRME : $4.63M
Gross Profit (TTM) NTLA : -$34.30M PRME : $0.00
EBITDA (TTM) NTLA : -$322.22M PRME : -$195.76M

Returns By Period

In the year-to-date period, NTLA achieves a 42.60% return, which is significantly higher than PRME's 0.29% return.

NTLA

• 1D: 10.04%
• 1M: -6.97%
• YTD: 42.60%
• 6M: -25.77%
• 1Y: 80.31%
• 3Y*: -29.93%
• 5Y*: -30.67%
• 10Y*: —

PRME

• 1D: 10.48%
• 1M: -24.68%
• YTD: 0.29%
• 6M: -37.18%
• 1Y: 74.87%
• 3Y*: -34.35%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NTLA vs. PRME — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA

NTLA Risk / Return Rank: 66
NTLA Sharpe Ratio Rank: 70
NTLA Sortino Ratio Rank: 71
NTLA Omega Ratio Rank: 73
NTLA Calmar Ratio Rank: 61
NTLA Martin Ratio Rank: 58

PRME

PRME Risk / Return Rank: 68
PRME Sharpe Ratio Rank: 65
PRME Sortino Ratio Rank: 74
PRME Omega Ratio Rank: 66
PRME Calmar Ratio Rank: 70
PRME Martin Ratio Rank: 63

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTLA vs. PRME - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Prime Medicine Inc. Common Stock (PRME). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NTLA	PRME	Difference
Sharpe ratio Return per unit of total volatility	0.80	0.67	+0.13
Sortino ratio Return per unit of downside risk	1.60	1.78	-0.18
Omega ratio Gain probability vs. loss probability	1.23	1.19	+0.04
Calmar ratio Return relative to maximum drawdown	0.83	1.42	-0.59
Martin ratio Return relative to average drawdown	1.48	2.29	-0.81
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NTLA vs. PRME - Sharpe Ratio Comparison

The current NTLA Sharpe Ratio is 0.80, which is comparable to the PRME Sharpe Ratio of 0.67. The chart below compares the historical Sharpe Ratios of NTLA and PRME, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NTLA	PRME	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.80	0.67	+0.13
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.38	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	-0.39	+0.32

Correlation

The correlation between NTLA and PRME is 0.58, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

NTLA vs. PRME - Dividend Comparison

Neither NTLA nor PRME has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NTLA vs. PRME - Drawdown Comparison

The maximum NTLA drawdown since its inception was -96.45%, roughly equal to the maximum PRME drawdown of -94.55%. Use the drawdown chart below to compare losses from any high point for NTLA and PRME.

Drawdown Indicators

	NTLA	PRME	Difference
Max Drawdown Largest peak-to-trough decline	-96.45%	-94.55%	-1.90%
Max Drawdown (1Y) Largest decline over 1 year	-71.27%	-52.77%	-18.50%
Max Drawdown (5Y) Largest decline over 5 years	-96.45%	—	—
Current Drawdown Current decline from peak	-92.75%	-83.52%	-9.23%
Average Drawdown Average peak-to-trough decline	-56.41%	-64.37%	+7.96%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.85%	32.70%	+7.15%

Volatility

NTLA vs. PRME - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) and Prime Medicine Inc. Common Stock (PRME) have volatilities of 21.45% and 21.00%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NTLA	PRME	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.45%	21.00%	+0.45%
Volatility (6M) Calculated over the trailing 6-month period	84.99%	66.76%	+18.23%
Volatility (1Y) Calculated over the trailing 1-year period	102.02%	112.28%	-10.26%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.71%	91.01%	-10.30%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.28%	91.01%	-12.73%

Financials